New Zealand markets open in 4 hours 39 minutes

Corvus Pharmaceuticals, Inc. (CRVS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.70+0.60 (+11.69%)
As of 01:20PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 319.01M
Enterprise value 272.47M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)6.23
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.36

Trading information

Stock price history

Beta (5Y monthly) 1.13
52-week change 3229.03%
S&P500 52-week change 326.33%
52-week high 36.00
52-week low 31.05
50-day moving average 33.30
200-day moving average 32.26

Share statistics

Avg vol (3-month) 3319.89k
Avg vol (10-day) 3498.13k
Shares outstanding 562.55M
Implied shares outstanding 662.55M
Float 838M
% held by insiders 14.02%
% held by institutions 144.79%
Shares short (30 Aug 2024) 41.43M
Short ratio (30 Aug 2024) 43.24
Short % of float (30 Aug 2024) 42.84%
Short % of shares outstanding (30 Aug 2024) 42.29%
Shares short (prior month 31 Jul 2024) 41.15M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)30 Jun 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-23.83%
Return on equity (ttm)-44.91%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -23.27M
Net income avi to common (ttm)-22.62M
Diluted EPS (ttm)-0.43
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)47.25M
Total cash per share (mrq)0.75
Total debt (mrq)700k
Total debt/equity (mrq)1.37%
Current ratio (mrq)3.62
Book value per share (mrq)0.82

Cash flow statement

Operating cash flow (ttm)-21.24M
Levered free cash flow (ttm)-5.98M